Abstract:To the Editor, Data regarding the real prevalence of pericardial involvement, and especially acute pericarditis, in coronavirus disease 2019 (COVID-19) patients are currently scant.1 The aim of the present manuscript is to perform a systematic review and meta-analysis to assess the pooled prevalence of pericarditis in COVID-19 patients at autopsy. Methods A literature search was performed using MEDLINE and Scopus databases from their inception to August 2021 to locate investigations in the English language reporting the autoptic prevalence of pericarditis in COVID-19 patients. The selection of studies to be included in our analysis was independently conducted by two authors (L.R., M.Z.) in a blinded fashion. Searches were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (Supplementary file 1, https://links.lww.com/JCM/A451). The search terms included the following MeSH terms: ‘COVID-19’ OR ‘SARS-CoV-2’ AND ‘pericarditis’ AND ‘autopsy’. Moreover, we searched the bibliographies of target studies for additional references. The final search was conducted on August 16, 2021. We predefined the inclusion criteria for eligible studies as follows: investigations reporting the autoptic prevalence of pericarditis in patients with a confirmed diagnosis of SARS-CoV-2 infection. Conversely, studies were excluded if they were case reports, review articles, editorials, letters and case series with <20 participants or they did not report sufficient data regarding the autoptic prevalence of pericarditis. The gathered data included author/s, sample size, mean age, gender, concomitant comorbidities such as arterial hypertension (HT), diabetes mellitus (DM), atrial fibrillation (AF), cancer, chronic obstructive pulmonary disease (COPD), heart failure (HF) and estimated prevalence of pericarditis at autopsy. The quality of included studies was graded using the Newcastle-Ottawa quality assessment scale (NOS). The cumulative autoptic prevalence of pericarditis in COVID-19 patients (n/N) was defined as the ratio between patients with histopathological findings of pericarditis (n) and the number of patients enrolled in each study (N). Data were pooled using a random-effects model and presented with the corresponding 95% confidence interval (CI). Between study heterogeneity was assessed using the Higgins I2 statistic and Q-value. The presence of potential publication bias was verified by visual inspection of the funnel plot. Due to the low number of included studies (<10), small-study bias was not examined as our analysis was underpowered to detect such bias. To further appraise the impact of potential baseline confounders, a meta-regression analysis was performed. All meta-analyses were conducted using Comprehensive Meta-Analysis software, version 3 (Biostat, USA). Results Using our search strategy, six studies met the inclusion criteria and were included into the final analysis (Fig. 1).2–7 Overall, 511 autopsies of COVID-19 patients (mean age 65.2 years, 345 males) were included in the analysis (Table 1). Quality assessment showed that all studies were of moderate-high quality according to the NOS scale.Fig. 1: Forest plot investigating the pooled autopsy prevalence of myocarditis in patients with COVID-19 infection. COVID-19, coronavirus disease 2019. Table 1 - General characteristics of the population enrolled Author No. of patients Age (SD) [range] Males, n (%) HT, n (%) DM, n (%) AF, n (%) Obesity, n (%) Cancer, n (%) COPD, n (%) HF, n (%) NOS Falasca et al. 3 22 76 (15)a48.5 (13.0)b 15 (68.1) 4 (22.3) 4 (22.3) 1 (4.5) NR 8 (44.5) 6 (33.3) NR 8 Basso et al. 4 21 69 [44–86] 15 (71) 16 (76) 7 (33) 4 (19) NR NR NR NR 7 Sang et al. 5 50 63.5 [31–94] 36 (72) 45 (90) 28 (56) NR 25 (50) NR NR 5 (10) 8 Bearse et al. 6 41 67 [21–89] 27 (65.8) 27 (65.8) 13 (31.7) NR NR NR NR NR 7 Halushka et al. 7 277 75 [22–27] 172 (62.1) 152 (54.9) 89 (32.1) NR 44 (15.9) 44 (15.9) 70 (25.3) NR 8 Diaz-Arocutipa et al. 8 100 54.8 (18.9) 80 (80) NR NR NR NR NR NR NR 6 aWith comorbidities.bWithout comorbidities.COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; HF, heart failure; HT, arterial hypertension; NOS, Newcastle-Ottawa quality assessment scale [investigations were classified as having low (<5 stars), moderate (5–7 stars) and high quality (>7 stars)]. Estimates for the prevalence of pericarditis at autopsy in COVID-19 patients ranged from 2.0% to 59.1% while the random-effects overall pooled estimated prevalence was 14.5% (95% CI: 5.8–31.7, I2 : 89.0%, P < 0.0001) (Fig. 1). Visual inspection of the relative funnel plot did not reveal significant evidence of publication bias (Supplementary file 2, https://links.lww.com/JCM/A452). Meta-regression showed a direct correlation with age (coefficient 0.015, P = 0.002) and gender (male vs. female, coefficient 0.016, P = 0.03), but no effect when considering arterial hypertension (P = 0.08), and diabetes mellitus (P = 0.60) as moderating variables. Comment Our results showed that the overall pooled prevalence of pericarditis among COVID-19 patients who underwent autopsy is 14.5%. Moreover, the histopathological findings were more common in male patients and influenced by increasing age, as demonstrated by the meta-regression performed. Probably, our results underestimate the real prevalence of acute pericarditis since they mainly reflect the prevalence in patients with more severe infection. Unfortunately, no specific data regarding the severity of the disease or need for intensive care unit hospitalization were reported in the original manuscripts as well as the concomitant prevalence of myocarditis. However, to date, the larger part of data on the prevalence of pericarditis in COVID-19 subjects has been obtained from clinical and radiological investigations, rather than from histopathological analyses.2,8 Most treatments for pericarditis do not appear contraindicated also in the presence of possible COVID-19 infection and should not be discontinued, and some (corticosteroids, colchicine, and anakinra) can be considered to treat both conditions.9 The observed epidemiological aspects are in accordance with previous studies performed in non-COVID-19 subjects, which demonstrated that acute pericarditis is more common in male patients; furthermore, also aging resulted to be associated with a higher in-hospital mortality among these patients.10 Notably, the same demographical issues have been also related to a higher mortality risk in COVID-19 patients,11 representing a common risk factor. The high heterogeneity observed may be also due to the limited number of studies satisfying the inclusion criteria of our analysis as well as the relatively few numbers of enrolled patients. In addition, also the inherited biases derived from the original investigations may have further contributed to the heterogeneity level observed. Moreover, different levels of methodological quality, sampling methods, professional level of the pathologists as well as adequate coverage of the identified sample may have produced significant difference among studies. The absence of a systemic autoptic screening in these patients may have underestimated the prevalence of pericarditis in COVID-19 patients who died as well as in those who survived since the diagnosis was suspected only in patients with evident clinical symptoms and/or high degree of suspicion. Therefore, despite the limited generalizability of our results to a non-autoptic COVID-19 population, acute pericarditis remains an important and underrecognized cardiovascular complication in COVID-19 patients which requires a proper workup and specific management. Conflicts of interest There are no conflicts of interest.

Serendipitous Adrenal Hyperplasia in Patients Admitted to the Emergency Department for Suspected SARS-CoV-2 Infection is Linked to Increased Mortality

Impact of coronavirus disease 2019 on patients with primary adrenal insufficiency: a cross-sectional study

The Adrenal Cortex, an Underestimated Site of SARS-CoV-2 Infection

The Spectrum of Adrenal Lesions in a Tertiary Referral Center

Increased Adrenal Steroidogenesis and Suppressed Corticosteroid Responsiveness in Critical COVID-19

Hypothalamic-Pituitary-Adrenal Axis Activity in SARS-CoV-2 Infected Noncritically Ill Hospitalized Patients

The existence of adrenal insufficiency in patients with COVID-19 pneumonia

Reversible central adrenal insufficiency in survivors of COVID19: results from a 24-month longitudinal study

Autoptic Prevalence of Pericarditis in Coronavirus Disease 2019 Patients

Inflammatory Cell Infiltration of Adrenals in COVID-19

Could the presence of adrenal incidentaloma negatively affect COVID 19 outcomes?

OR12-4 Metabolic Profiling in Adrenal Tumors Demonstrates Enhanced Chronic Inflammation, Branched Chain Amino Acids and Ketone Bodies, Biomarkers that Predict High Cardiometabolic Risk

Relationship Between Adrenal Function and Prognosis in Patients with Severe Sepsis

A SYSTEMATIC REVIEW AND META-ANALYSIS ABOUT THE PREVALENCE OF FUNCTIONING ADRENAL INCIDENTALOMAS

Enhanced chronic inflammation and increased branched chain amino acids in adrenal disorders: a cross-sectional study

Clinical features and practice patterns of treatment for adrenal crisis: a nationwide cross-sectional study in Japan

Outcomes Associated with the use of High Dose Corticosteroids and IL-6 Inhibitors for the Treatment of Acute Respiratory Distress Syndrome Secondary to SARS COV-2

Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors

Adrenal Hemorrhage: A Comprehensive Analysis of a Heterogeneous Entity—Etiology, Presentation, Management, and Outcomes

Course of COVID-19 infection in patients with congenital adrenal hyperplasia

Clinical study of the adrenal function change of sepsis patients